FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2460303553> ?p ?o ?g. }

• W2460303553 endingPage "44298" @default.
• W2460303553 startingPage "44288" @default.
• W2460303553 abstract "// Ke Wang 1 , Jianjun Xu 2 , Tao Zhang 1 , Dan Xue 3 1 Department of Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China 2 School of Finance, Zhejiang University of Finance and Economics, Hangzhou, 310018, China 3 Department of Plastic Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China Correspondence to: Dan Xue, email: zxkdanxue@126.com Keywords: breast cancer, lymphocyte infiltrates, pathological complete response (pCR), prognosis, meta-analysis Received: February 23, 2016      Accepted: May 17, 2016      Published: June 13, 2016 ABSTRACT Tumor-infiltrating lymphocytes (TILs) influence tumor prognosis and the chemotherapeutic response. Here, we quantified the clinical relevance of TILs, including the effect of TILs on lymphocyte subpopulations and assessed their consistency in breast cancer. We searched published literature from January 2000 to January 2016. The main parameters analyzed were pathological complete response (pCR) and survival outcome following chemotherapy in patients with breast cancer. Pooled odds ratio (OR) or relative risk (RR) values with 95% confidence intervals (CIs) were computed using random and fixed-effects models. Subgroup and heterogeneity analyses were also conducted. Twenty-three studies, which included 13,100 patients, met the inclusion criteria. The pooled results showed that TILs were associated with clinicopathological parameters of biologically aggressive phenotypes, such as high tumor grade or estrogen/progesterone receptor negativity, but they were not correlated with human epidermal growth factor receptor-2 expression. Moreover, a high TIL level was associated with a significantly improved pCR rate compared with a low TIL level (OR, 2.81; P < 0.001), particularly in the triple-negative breast cancer subtype (OR, 4.67; P < 0.001). An analysis of lymphocyte subpopulations showed that infiltration by CD8 lymphocytes, but not by CD4 lymphocytes and Foxp3 cells, was associated with a high pCR rate. Furthermore, a high TIL level was associated with significantly longer disease-free survival and overall survival. Our present meta-analysis indicates that an increased number of TILs predicted pCR to chemotherapy and improved survival. A high TIL level, characterized mainly by the infiltration of CD8 lymphocytes, is a strong predictive and prognostic factor." @default.
• W2460303553 created "2016-07-22" @default.
• W2460303553 creator A5035701638 @default.
• W2460303553 creator A5041057625 @default.
• W2460303553 creator A5064261255 @default.
• W2460303553 creator A5071019594 @default.
• W2460303553 date "2016-06-13" @default.
• W2460303553 modified "2023-10-17" @default.
• W2460303553 title "Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis" @default.
• W2460303553 cites W1906698094 @default.
• W2460303553 cites W1975401903 @default.
• W2460303553 cites W1979250236 @default.
• W2460303553 cites W2003804967 @default.
• W2460303553 cites W2006070721 @default.
• W2460303553 cites W2009098155 @default.
• W2460303553 cites W2018695684 @default.
• W2460303553 cites W2036704696 @default.
• W2460303553 cites W2044928979 @default.
• W2460303553 cites W2046016820 @default.
• W2460303553 cites W2053662475 @default.
• W2460303553 cites W2075642745 @default.
• W2460303553 cites W2076952890 @default.
• W2460303553 cites W2081177143 @default.
• W2460303553 cites W2081427413 @default.
• W2460303553 cites W2085234652 @default.
• W2460303553 cites W2085524041 @default.
• W2460303553 cites W2098683355 @default.
• W2460303553 cites W2113479349 @default.
• W2460303553 cites W2125885282 @default.
• W2460303553 cites W2134878729 @default.
• W2460303553 cites W2135298509 @default.
• W2460303553 cites W2142153200 @default.
• W2460303553 cites W2152276633 @default.
• W2460303553 cites W2157058802 @default.
• W2460303553 cites W2157668335 @default.
• W2460303553 cites W2160332393 @default.
• W2460303553 cites W2162794483 @default.
• W2460303553 cites W2163035374 @default.
• W2460303553 cites W2163871197 @default.
• W2460303553 cites W2178133357 @default.
• W2460303553 cites W2313168486 @default.
• W2460303553 cites W2560367415 @default.
• W2460303553 doi "https://doi.org/10.18632/oncotarget.9988" @default.
• W2460303553 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5190096" @default.
• W2460303553 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27329588" @default.
• W2460303553 hasPublicationYear "2016" @default.
• W2460303553 type Work @default.
• W2460303553 sameAs 2460303553 @default.
• W2460303553 citedByCount "83" @default.
• W2460303553 countsByYear W24603035532016 @default.
• W2460303553 countsByYear W24603035532017 @default.
• W2460303553 countsByYear W24603035532018 @default.
• W2460303553 countsByYear W24603035532019 @default.
• W2460303553 countsByYear W24603035532020 @default.
• W2460303553 countsByYear W24603035532021 @default.
• W2460303553 countsByYear W24603035532022 @default.
• W2460303553 countsByYear W24603035532023 @default.
• W2460303553 crossrefType "journal-article" @default.
• W2460303553 hasAuthorship W2460303553A5035701638 @default.
• W2460303553 hasAuthorship W2460303553A5041057625 @default.
• W2460303553 hasAuthorship W2460303553A5064261255 @default.
• W2460303553 hasAuthorship W2460303553A5071019594 @default.
• W2460303553 hasBestOaLocation W24603035531 @default.
• W2460303553 hasConcept C121608353 @default.
• W2460303553 hasConcept C126322002 @default.
• W2460303553 hasConcept C143998085 @default.
• W2460303553 hasConcept C156957248 @default.
• W2460303553 hasConcept C2777701055 @default.
• W2460303553 hasConcept C2778326572 @default.
• W2460303553 hasConcept C44249647 @default.
• W2460303553 hasConcept C530470458 @default.
• W2460303553 hasConcept C71924100 @default.
• W2460303553 hasConcept C84606932 @default.
• W2460303553 hasConcept C95190672 @default.
• W2460303553 hasConceptScore W2460303553C121608353 @default.
• W2460303553 hasConceptScore W2460303553C126322002 @default.
• W2460303553 hasConceptScore W2460303553C143998085 @default.
• W2460303553 hasConceptScore W2460303553C156957248 @default.
• W2460303553 hasConceptScore W2460303553C2777701055 @default.
• W2460303553 hasConceptScore W2460303553C2778326572 @default.
• W2460303553 hasConceptScore W2460303553C44249647 @default.
• W2460303553 hasConceptScore W2460303553C530470458 @default.
• W2460303553 hasConceptScore W2460303553C71924100 @default.
• W2460303553 hasConceptScore W2460303553C84606932 @default.
• W2460303553 hasConceptScore W2460303553C95190672 @default.
• W2460303553 hasIssue "28" @default.
• W2460303553 hasLocation W24603035531 @default.
• W2460303553 hasLocation W24603035532 @default.
• W2460303553 hasLocation W24603035533 @default.
• W2460303553 hasLocation W24603035534 @default.
• W2460303553 hasOpenAccess W2460303553 @default.
• W2460303553 hasPrimaryLocation W24603035531 @default.
• W2460303553 hasRelatedWork W1996753309 @default.
• W2460303553 hasRelatedWork W2027893081 @default.
• W2460303553 hasRelatedWork W2047252483 @default.
• W2460303553 hasRelatedWork W2074274808 @default.
• W2460303553 hasRelatedWork W2150701277 @default.
• W2460303553 hasRelatedWork W2286371484 @default.

• next